Advertisement
The immunogenicity of biological drugs can often be a significantobstacle in the development of successful new therapies. Unwantedimmunogenicity can manifest itself particularly through anti-drug antibody(ADA) responses. These responses can lead to allergic reactions, reduction orneutralization of the activity of the drug and, in some cases, cross-reactiveimmune responses, which could lead to serious adverse events.
Advertisement
ProImmune's new REVEAL(TM) Immunogenicity System combines, for the firsttime, cell-free HLA-peptide binding assays for more than 50 class II HLAalleles, with highly sensitive T cell proliferation assays. This combinationenables the creation of a detailed profile of the helper T cell immuneresponse to one or more drug leads. The role of helper T cells is known to beof critical importance in controlling unwanted anti-drug antibody responses.If desired, the leads analyzed can then be re-engineered to remove unwantedhelper T cell epitopes and produce a re-validated drug lead with improvedimmunogenicity risk.
Dr. Nikolai Schwabe, CEO of ProImmune, said: "Our experienced scientistshave brought together an unrivalled range of physical class II HLA bindingassays and sensitive T cell assays for predicting immunogenicity risk. TheREVEAL(TM) System sets a new paradigm for immunogenicity risk management atthe pre-clinical stage. It is a natural evolution of ProImmune's leadingtechnology platforms in T cell immunology."
ProImmune provides the REVEAL(TM) Immunogenicity System as a highlycustomizable service, purely on a 'fee for service' basis.
Notes to Editors:
About ProImmune - http://www.proimmune.com
ProImmune is a private biotechnology company with its headquarters inOxford, UK, that specializes in providing products and services for epitopediscovery, immune monitoring and the design of biological drugs with reducedimmunogenicity risk. ProImmune has a wide range of customers from leadingpharmaceutical and biotechnology companies, as well as clinical and academicresearch institutes throughout the world.
SOURCE ProImmune Ltd
